Actavis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.07.14	FTC Puts Conditions On Actavis Deal To Buy Forest Laboratories (RTTNews)
30.06.14	Actavis Confirms Generic Zubsolv Patent Challenge - Quick Facts (RTTNews)
19.06.14	Actavis Confirms Court Ruling In Generic Exelon Patch Patent Suit (RTTNews)
14.05.14	Actavis Plans New Leadership Team Post Forest Labs. Acquisition - Quick Facts (RTTNews)
12.05.14	Actavis Settles Patent Litigation Related To Its Generic Version Of Acanya (RTTNews)
01.04.14	Actavis Buys Silom Medical For $100 Mln In Cash - Quick Facts (RTTNews)
18.02.14	Milliarden-Übernahme wirbelt Pharmabranche auf (AWP)
18.02.14	Mega-Deal in US-Pharmabranche: Actavis will Forest Labs schlucken (AF) (AWP)
18.02.14	Mega-Deal in US-Pharmabranche: Actavis will Konkurrent Forest Labs kaufen (AWP)
18.02.14	Kreise: Actavis vor Milliardenübernahme in US-Pharmabranche (2. AF) (AWP)
18.02.14	Actavis vor Milliardenübernahme in US-Pharmabranche (AWP)
18.02.14	Actavis will US-Konkurrent Forest Laboratories (AWP)
18.02.14	SMI schliesst leicht im Plus -- Dax trotzt Gegenwind -- Europas Börsen bewegen sich kaum -- US-Börsen schliessen uneinheitlich -- Moody's warnt Schweiz und ihre Banken (finanzen.ch)
24.12.13	FDA Seeks More Details On Actavis' NDA For Progestin-only Contraceptive Patch (RTTNews)
14.11.13	Actavis Confirms Generic Axiron Patent Challenge (RTTNews)
29.10.13	Actavis Q3 Adj. Earnings Matches View, Lifts Full-year Outlook - Quick Facts (RTTNews)
14.10.13	Clinical Trial Results, Conference Calls, and Acquisitions - Research Report on Pfizer, UnitedHealth, Actavis, Bristol-Myers Squibb, and Quest Diagnostics (PR Newswire)
02.10.13	Actavis, Inc. -- Correction to Text, October 1, 2013 Release: Moody's Affirms Actavis' Ratings; Upgrades Warner Chilcott's Senior Notes to Baa3 (Moodys)
02.10.13	Actavis plc Names Board of Directors (PR Newswire)
01.10.13	Actavis, Inc. -- Moody's Affirms Actavis' Ratings; Upgrades Warner Chilcott's Senior Notes to Baa3 (Moodys)
01.10.13	Today's Technical View: Avanir Pharmaceuticals Inc., Warner Chilcott PLC, Actavis Inc., and Dynavax Technologies Corp. (PR Newswire)
01.10.13	Actavis Completes Warner Chilcott Acquisition (PR Newswire)
27.09.13	Actavis and Warner Chilcott Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott (PR Newswire)
26.09.13	Regulatory Approvals, Positive Stock Price Movements, Optimistic Clinical Data, and New Launches and Contracts - Research Report on Johnson & Johnson, Celldex, Isis, Actavis, and Centene (PR Newswire)
25.09.13	Actavis, Inc. to Host Third Quarter 2013 Earnings Conference Call and Webcast (PR Newswire)
25.09.13	OXYTROL® FOR WOMEN, the First Over-the-Counter Treatment for Overactive Bladder in Women, Now Available Nationwide (PR Newswire)
17.09.13	Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien (PR Newswire)
13.09.13	New Products, Philanthropic Initiative, Approved Acquisitions, and Pipeline Developments Boost Growth - Research Report on Mylan, UnitedHealth, GSK, Actavis, and Mallinckrodt (PR Newswire)
12.09.13	Actavis Launches Generic Version of Opana® ER (PR Newswire)
10.09.13	Actavis and Warner Chilcott Shareholders Approve Proposals Related to Actavis' Proposed Acquisition of Warner Chilcott (PR Newswire)
30.08.13	Launch of New Services, Acquisitions, Investments, New Research Facilities and Pending FDA Approvals - Research Report on UnitedHealth, Hi-Tech, Thermo Fisher, Covidien, and Actavis (PR Newswire)
29.08.13	Actavis' Proposed Acquisition of Warner Chilcott Recommended for Approval by Leading Proxy Advisory Firms (PR Newswire)
28.08.13	Today's Research: Avanir Pharmaceuticals Inc., Warner Chilcott plc, Actavis Inc., and Dynavax Technologies Corp. (PR Newswire)
27.08.13	Actavis Confirms Generic Rayos® Patent Challenge (PR Newswire)
16.08.13	Actavis Names James D'Arecca Chief Accounting Officer (PR Newswire)
09.08.13	Actavis Receives Approval from French Competition Authority for Pending Warner Chilcott Acquisition (PR Newswire)
08.08.13	Regulatory Approvals, Ongoing Clinical Trials, Divestures, New Borrowings and Regulatory Applications - Research Report on Zoetis, GSK, Actavis, Kindred Healthcare, TESARO (PR Newswire)
06.08.13	Actavis Acquires Worldwide Rights for Palau Pharma's Albaconazole Antifungal Agent (PR Newswire)
31.07.13	Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4 (PR Newswire)
30.07.13	Regulatory Approvals, Product Launches, and Steady Sales Show Signs of Growth - Research Report on Johnson & Johnson, Bristol-Myers Squibb, Actavis, Edwards Lifesciences, and Health Net (PR Newswire)
29.07.13	Actavis Confirms Generic Nucynta® ER Patent Challenge (PR Newswire)
25.07.13	Actavis Announces 42% Increase to $2.01 in Second Quarter 2013 Non-GAAP Earnings Per Share (PR Newswire)
23.07.13	Today's Technical View: Dynavax Technologies, Avanir Pharma, Warner Chilcott, and Actavis (PR Newswire)
19.07.13	Actavis stellt Geschäftsbereiche in Europa auf den Prüfstand - Verkauf möglich (AWP)
12.07.13	Actavis Files ANDA For Generic Version Of Anticonvulsant Drug Vimpat (RTTNews)
11.07.13	FTC Seeks Addl Information On Actavis' Pending Acquisition Of Warner Chilcott (RTTNews)
20.05.13	Actavis will Warner Chilcott für 8,5 Milliarden US-Dollar kaufen (AF) (AWP)
20.05.13	Actavis will Warner Chilcott für 8,5 Milliarden Dollar kaufen (AWP)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.42	1.94 %	K V
UBS Group	28.08	1.48 %	K V
Part Grp Hldg	1’268.50	1.16 %	K V
ABB	49.48	0.94 %	K V
Swiss Re	129.65	0.74 %	K V
Alcon	78.12	0.15 %	K V
Nestle	76.26	-0.13 %	K V
CieFinRichemont	121.35	-0.45 %	K V
Sonova Hldg	301.90	-0.69 %	K V
Givaudan	3’850.00	-0.77 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Actavis Inc

Aktien Top/Flop

Actavis Peer Group Nachrichten

Meistgelesene Nachrichten